Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET Study of preservative-free latanoprost versus Xalatan in POAG or ocular hypertension
2021-000147-45Phase 3Completed
- Sponsor
- Yonsung Fine Chemical
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Yonsung Fine Chemical. Primary endpoint: Primary efficacy endpoint. Started Mar 2021; status: completed.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2021-000147-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000147-45.